Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
Open Access
- 3 June 2021
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 28 (10) , 3418-3425
Abstract
Background and purpose: Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of coronavirus 2019 (COVID‐19) mainly due to respiratory muscle weakness, older age and long‐term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID‐19 in MG patients and risk of MG exacerbation during COVID‐19.Methods: We evaluated clinical features and outcomes after COVID‐19 in 93 MG patients.Results: Thirty‐five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID‐19. Higher forced vital capacity (FVC) values tested before COVID‐19 were shown to be protective against severe infection (95% CI 0.934–0.98) as well as good control of MG measured by the quantified myasthenia gravis score (95% CI 1.047–1.232). Long‐term chronic corticosteroid treatment worsened the course of COVID‐19 in MG patients (95% CI 1.784–111.43) and this impact was positively associated with dosage (p = 0.005). Treatment using azathioprine (95% CI 0.448–2.935), mycophenolate mofetil (95% CI 0.91–12.515) and ciclosporin (95% CI 0.029–2.212) did not influence the course of COVID‐19. MG patients treated with rituximab had a high risk of death caused by COVID‐19 (95% CI 3.216–383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir (95% CI 0.885–10.87).Conclusions: As the most important predictors of severe COVID‐19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long‐term corticosteroid treatment especially in higher doses, older age, the presence of cancer, and recent rituximab treatment.Keywords
Funding Information
- Všeobecná Fakultní Nemocnice v Praze (GIP‐20‐L‐14‐212)
- Ministerstvo Zdravotnictví Ceské Republiky (FNBr 65269705)
- Masarykova Univerzita (MUNI/A/1600/2020)
This publication has 34 references indexed in Scilit:
- Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysisEuropean Respiratory Journal, 2020
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Factors associated with acute exacerbations of myasthenia gravisMuscle & Nerve, 2019
- Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort studyTravel Medicine and Infectious Disease, 2019
- Myasthenia gravis and infectious diseaseJournal of Neurology, 2018
- Infection Risk and Safety of Corticosteroid UseRheumatic Disease Clinics of North America, 2016
- The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literatureJournal of Neurology, 2011
- [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)].1996
- High IL‐6 Gene Expression and Production by Cultured Human Thymic Epithelial Cells from Patients with Myasthenia GravisAnnals of the New York Academy of Sciences, 1993